{"id":"NCT03421379","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus","officialTitle":"A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients With Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-21","primaryCompletion":"2018-08-20","completion":"2018-08-20","firstPosted":"2018-02-05","resultsPosted":"2019-10-08","lastUpdate":"2019-10-08"},"enrollment":75,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Glucagon Nasal Powder","otherNames":["LY900018"]},{"type":"DRUG","name":"Glucagon Hydrochloride Solution","otherNames":["GlucaGenÂ®"]}],"arms":[{"label":"Glucagon Nasal Powder","type":"EXPERIMENTAL"},{"label":"Glucagon Hydrochloride Solution","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus.","primaryOutcome":{"measure":"Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia","timeFrame":"Pre-dose up to 30 minutes post each glucagon administration","effectByArm":[{"arm":"Glucagon Nasal Powder","deltaMin":100,"sd":null},{"arm":"Glucagon Hydrochloride Solution","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":["38444629"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Nausea","Vomiting","Rhinalgia","Blood pressure increased","Blood pressure decreased"]}}